Contemporary clinical management of monomorphic idiopathic premature ventricular contractions: results of the European Heart Rhythm Association survey

Europace. 2022 Jul 15;24(6):1006-1014. doi: 10.1093/europace/euab307.

Abstract

On behalf of the European Heart Rhythm Association, we designed a survey, whose aim was to understand the trend(s) in the clinical management of idiopathic monomorphic premature ventricular contractions (PVCs) among European cardiologists and cardiac electrophysiologists. A total of 202 participants in the survey answered 27 multiple-choice questions on the clinical presentation, diagnosis and treatment of idiopathic monomorphic PVCs. The most common symptom in patients with idiopathic monomorphic PVCs is palpitations, according to the majority of responders (87%), followed by fatigue (29%) and dizziness (18%). Complete blood cell count, renal function with electrolytes levels, and thyroid function are the blood tests requested by the majority of respondents (65%, 92%, and 93%, respectively). Coronary artery disease and structural heart disease needs to be ruled out, according to the vast majority of participants (99%). A 24-h Holter ECG is the preferred ECG modality to assess the burden of PVCs (86% of respondents). Among the different option treatments, beta-blockers and class I antiarrhythmic drugs are by far (81% of respondents) the preferred pharmacological option in comparison with calcium antagonists and class III antiarrhythmic drugs. Catheter ablation has also a good reputation: 99% of responders are keen to use it, especially in patients with high burden of PVCs and when signs of cardiomyopathy occur.

Keywords: Antiarrhythmic drugs; Cardiomyopathy; Catheter ablation; EHRA survey; Idiopathic; Premature ventricular contraction; Ventricular arrhythmias.

MeSH terms

  • Anti-Arrhythmia Agents / therapeutic use
  • Catheter Ablation*
  • Humans
  • Surveys and Questionnaires
  • Treatment Outcome
  • Ventricular Premature Complexes* / diagnosis
  • Ventricular Premature Complexes* / therapy

Substances

  • Anti-Arrhythmia Agents